Precision Health Reports’ Post

Cancer treatment can take a significant toll not just on physical health, but also on financial well-being. Financial toxicity, the economic burden associated with cancer treatment, can devastate a patient’s physical and emotional state. It is crucial to understand how finances influence medical decision-making and the resources available to help manage this burden. Why Finances Matter in Medical Decisions: Financial stress can lead to delayed treatments, skipped medications, or choosing less effective therapies. Patients might prioritize costs over the most suitable medical options, potentially compromising their health outcomes. Proactive Steps to Mitigate Financial Toxicity: 1. Understand Your Health Insurance 2. Discuss Costs with Providers 3. Seek Assistance By taking these steps, individuals can reduce their risk of financial hardship associated with cancer care. These measures help ease stress and enable patients to focus more fully on their health and healing journey. Qualify Health is here to support you through this challenging time, offering resources and assistance to help manage the financial impact of cancer treatment. Let us help you focus on what truly matters: your recovery and well-being. Visit us to know more: https://lnkd.in/dR2C4cMJ For Service call: + 1 864 650 6400 or, [email protected] #FinancialToxicity #CancerCare #PatientOutcomes #HealthFinances #CancerTreatmentCosts #MedicalDecisionMaking #HealthcareCosts #InsuranceCoverage #FinancialAssistance #QualifyHealth #CancerSupport #HealthJourney #PatientWellBeing #CancerAwareness #FinancialHealth

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation in patients with obesity but without diabetes. https://lnkd.in/eKG_SN-4

Dr. Haggerty has published a lot of papers, but this may be one of the most important ones. With her research team, she conceptualized it, implemented it, and published it amazingly quickly. Patients around the country are experiencing unprecedented benefits from GLP1 anti-obesity medications only to have access to those medications stripped from them mid-treatment if insurance plans stop coverage. This is the first qualitative study to assess the impact on these patients. Insurances must do better. They should have strategies to get the right people on the right treatments for obesity and should not take people doing well off of treatment. https://lnkd.in/eq5RV97R

Although healthcare inflation remains a major challenge, it’s heartening to see a return to relative stability, at least in the Individual market. Coming out of COVID-19, a period of tremendous volatility in prices, utilization, and risk pool stability, this analysis by the American Academy of Actuaries (https://lnkd.in/grs8tsqW) provides a glimpse of relief in the year ahead. This shift presents us with a golden opportunity to refocus on prevention at all levels: primary, secondary, and tertiary. Close to 30 cents of every healthcare dollar are spent on services that could be avoided through preventive care. Preventative measures are not just about reducing costs —they're about enhancing quality of life, managing long-term risks, and fostering a healthier society. With prescription costs on the rise, driven by novel treatments like GLP-1s and gene therapies, and chronic conditions becoming more prevalent, it's imperative that we invest in prevention as the most cost-effective way to combat healthcare inflation and better manage risk. Let's embrace this moment to innovate and strengthen our preventive strategies #Healthcare #Prevention #Wellness

💡A new study has estimated the prevalence of paroxysmal nocturnal hemoglobinuria in adult patients with insurance in the United States from 2018 to 2022, along with describing the associated healthcare resource utilization and costs of #C5Inhibitors including #eculizumab, #pegcetacoplan, and #ravulizumab. Read the findings here: https://brnw.ch/21wLfqq #RareDiseaseResearch

📣 This is a welcome development for patients who have been waiting and lobbying for a PhilHealth benefit package. According to the news 📰, the categories are: heart attacks, 10 rare diseases, preventive oral health in primary care, peritoneal dialysis, and assistive mobility devices. These benefits, endorsed for Board approval, include: 👉 A package for acute myocardial infarction (AMI) or heart attacks across the continuum of care. 👉 Coverage for ten rare diseases, including Maple Syrup Urine Disease, Methylmalonic Acidemia/Propionic Acidemia, Galactosemia, Phenylketonuria, Gaucher Disease, Pompe Disease, Fabry Disease, MPS II (Hunter Syndrome), MPS IV (Morquio Syndrome), and Osteogenesis Imperfecta. 👉 Preventive oral health services to complement the PhilHealth Konsulta package. 👉 Improved coverage for peritoneal dialysis. 👉 Assistive mobility devices for priority conditions to support those most in need of physical rehabilitation. I hope that all these benefit packages will be comprehensive, covering everything from screening to diagnosis to treatment. At the Philippine Alliance of Patient Organizations, we have been advocating for complete packages of care to ensure that patients do not encounter challenges or fall through the gaps. Without a complete benefit package, financially challenged patients may still struggle to access care. Another major challenge is out-of-pocket expenses. The co-pay will depend on the patient's financial capacity. Hopefully, these benefit packages will be accessible to all patients in need, especially the disadvantaged. https://lnkd.in/gi8Uziv6

Now Open for Applications! 🌟 The Thrombotic Thrombocytopenic Purpura, or TTP, Program is now accepting applications. Program space is limited and offered on a first-come, first-served basis. This financial assistance program is designed to help eligible individuals manage costs like medication copays, health insurance premiums, and travel expenses related to their care. TTP is a rare, life-threatening disorder that causes blood clots to form in small blood vessels throughout the body. These clots can limit or block vessels, restricting blood flow to organs such as the brain, kidneys, and heart. With early intervention, it is possible to improve long-term outcomes for those with TTP. Start your application today to see how we can help cover your healthcare costs! 🔗 https://lnkd.in/eaDETp8A #AccessiaHealth #PatientAssistance #TTP #FinancialAssistance #TTPAwareness #BloodDisorder #Hematology #PatientSupport

🚨 New Study Reveals Key Insights on Semaglutide Use Among Obese Patients! 🚨 A recent analysis sheds light on how insurance type and gender significantly influence the initiation of semaglutide treatment for obesity in the U.S. 🏥 🔍 Key Findings: - Only 2.0% of diagnosed individuals began treatment within six months. - Women are over twice as likely to start semaglutide compared to men. - Antidepressant use and point-of-service insurance plans correlate with higher initiation rates. 📊 The study highlights the critical role of insurance structures in accessing obesity treatments, emphasizing a need for policy revisions to enhance coverage and simplify access. 💡 Let's work towards more equitable treatment opportunities! For a deeper dive into these findings, click on the link! #ClinicalResearches #HealthcareAccess #InsuranceImpact #ObesityManagement #PublicHealth #Publications #RegulatoryAgencies #Semaglutide #MarketAccess #MarketAccessToday

Is $2,000,000 the new $1,000,000? ^ I'll get to this in a second... Tokio Marine HCC just released their 2024 Annual Market Report, and I'd highly recommend anyone in the health insurance space to spend some time with it. My key takeaways below: ➡ Cancer, cardiovascular, and MSK comprise nearly half of total stop loss spend. ➡ High-cost gene therapy (GT) is quickly gaining approval; in 2021 there were 2 approved GTs, now there are 14 GTs and growing. ➡ When comparing pre-ACA (Affordable Care Act and the removal of lifetime max's) to post-ACA; the number of policies expected to have a large claim ($500k over the spec) went from 92 to 76 to 45. And finally ➡ When looking at avg. claims severity over the past 4 years, the avg. stop loss reimbursement over $1M has increased 15%. Compare that to the avg. stop loss reimbursement over $2M and it's an increase of 16.5%. What does all this mean? Claims continue to get more severe with more frequency, driven by a handful of diagnostic categories, due in large part to GT and the accelerant we've seen on instances of large claims per policy since 2014. The $2M benchmark is beginning to feel like the $1M benchmark, which is a major problem for employers providing healthcare benefits for their employees. ParetoHealth creates an opportunity for businesses to self-fund which puts them in the driver's seat of their healthcare spend, then leverages best in class cost containment tools to give those employers unique solutions to curb some of those large costs. I can't see into the future, but something tells me the Annual Market Reports for 2025, 2026, and beyond will be a lot of the same. To reference an old phrase... Question: When is the best time to plant a tree? Answer: 20 years ago Question: When is the second best time to plant a tree? Answer: Now #healthcare #healthinsurance #expenses #stoploss